Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06921850 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
A Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT06921850: Recruiting Phase 3 study of Hidradenitis Suppurativa, sponsored by UCB Biopharma SRL.
NCT06921850 is a Phase 3 study of Hidradenitis Suppurativa that is actively recruiting participants, run by UCB Biopharma SRL. The registered enrollment target is 40 participants, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (93% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06921850, a Phase 3 study of Hidradenitis Suppurativa, is actively recruiting participants, sponsored by UCB Biopharma SRL.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Primary Outcome
Plasma samples will be collected prior to dosing for measurement of plasma concentrations of bimekizumab at the specified timepoint.
Conditions Studied
Interventions
- DRUG Bimekizumab
Study Locations (17)
Other
- Hs0006 40326 - Berlin
- Hs0006 40747 - Mainz
- Hs0006 40625 - Warsaw
- Hs0006 40761 - Warsaw
- Hs0006 40095 - Wroclaw
- Hs0006 40845 - Wroclaw
Michigan
- Hs0006 50178 - Clarkston
- Hs0006 50710 - Fort Gratiot
- Hs0006 50711 - Troy
Arizona
- Hs0006 50175 - Phoenix
California
- Hs0006 50708 - Roseville
District of Columbia
- Hs0006 50707 - Washington D.C.
Florida
- Hs0006 50199 - Miami
New York
- Hs0006 50712 - Brooklyn
North Carolina
- Hs0006 50706 - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2029-03-06 |
| Phase | Phase 3 |
What NCT06921850 shows while recruiting
NCT06921850 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 597-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 1 intervention - of which Bimekizumab is the first listed.
NCT06921850 lists 17 locations in 10 states (Other, Michigan, Arizona).
Frequently Asked Questions
What is clinical trial NCT06921850 about?
NCT06921850 is a clinical study titled "A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa". The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
What is the current status of trial NCT06921850?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2025-04-07. Estimated completion is 2029-03-06.
What conditions does trial NCT06921850 study?
This clinical trial studies the following conditions: Hidradenitis Suppurativa.
What interventions are being tested in trial NCT06921850?
The interventions under investigation include: Bimekizumab (DRUG).
Who is sponsoring clinical trial NCT06921850?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06921850 being conducted?
This trial has 17 study locations across Arizona, California, District of Columbia, Florida, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hidradenitis Suppurativa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06921850's enrollment target sits among peer trials
40 35th of 52 higher than 18 of 52 other Hidradenitis Suppurativa trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI